Showing results (121-130 of 212) with videos related to
Sort By:
Pageof 22
Hemasphere|November 15, 2019
Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study GroupAlice Marceau-Renaut, Nicolas Duployez, Benoît Ducourneau, et al.Hemasphere|November 22, 2021
Improvement of Standardization of Molecular Analyses in Hematology: The 10-year GBMHM French ExperienceAnne Sophie Alary, Carole Maute, Olivier Kosmider, et al.Blood|May 22, 2010
Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remissionOlivier Nibourel, Olivier Kosmider, Meyling Cheok, et al.Oncotarget|February 22, 2018
SNP-array lesions in core binding factor acute myeloid leukemiaNicolas Duployez, Elise Boudry-Labis, Christophe Roumier, et al.American Journal of Hematology|March 6, 2013
Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemiaElise Boudry-Labis, Catherine Roche-Lestienne, Olivier Nibourel, et al.Acta Haematologica|June 15, 2026
Limited prognostic value of ELN classification and relevance of molecular ontogeny in acute myeloid leukemia post myeloproliferative neoplasms: a retrospective multicenter studyEdmond Chiche, Caroline Fileni, Sarah Bonnet, et al.Blood|June 22, 2011
Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 studyXavier Thomas, Mohamed Elhamri, Emmanuel Raffoux, et al.Cancers|January 8, 2020
Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex KaryotypeLaurène Fenwarth, Nicolas Duployez, Xavier Thomas, et al.Haematologica|December 10, 2020
Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical useAuriane Lesieur, Xavier Thomas, Olivier Nibourel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 studyCecile Pautas, Fatiha Merabet, Xavier Thomas, et al.Pageof 22